According to the lawsuit, the Offering (IPO) documents contained and defendants made false and/or misleading statements and/or failed to disclose that:
- the research conducted by the Company’s Chief Executive Officer and President, Leen Kawas, was tainted by Kawas’ scientific misconduct, including the manipulation of key data through the altering of Western blot images;
- this purported research was foundational to Athira’s efforts to develop treatments for Alzheimer’s because it laid the biological groundwork that Athira was using in its approach to treating Alzheimer’s;
- as a result, Athira’s intellectual property and product development for the treatment of Alzheimer’s was based on invalid research; and
- as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
